Debt (Additional Information) (Details) - USD ($)						1 Months Ended	3 Months Ended
	Sep. 21, 2023	Jul. 01, 2023	Jun. 27, 2023	Apr. 30, 2023	Mar. 21, 2023	Sep. 30, 2023	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Oct. 11, 2023
Debt Instrument [Line Items]
Principle amount of issued debt				$ 25,000,000
Repayment of debt prinnciple installment							$ 15,000,000	$ 0
Debt Instrument Redemption							The Company had the right, but not the obligation, in its sole discretion, to redeem, upon five business days’ prior written notice to Yorkville (the “Redemption Notice”), all or any portion of the amounts outstanding under the Convertible Debentures; provided that the trading price of the Common Stock is less than the Conversion Price at the time of the Redemption Notice. The redemption amount shall be equal to the outstanding principal balance being redeemed by the Company, plus the redemption premium of 10% of the principal amount being redeemed, plus all accrued and unpaid interest in respect of such redeemed principal amount.
Common stock, shares issued							166,189,835		160,084,250
Maximum [Member]
Debt Instrument [Line Items]
Debt conversion price										$ 2
Minimum [Member]
Debt Instrument [Line Items]
Debt conversion price										$ 0.5
Oramed Note
Debt Instrument [Line Items]
Principle amount of issued debt						$ 101,900,000
Net cash proceeds for direct offering							$ 9,578,835,000
Estimated fair value							$ 92,900,000
Securities Purchase Agreement [Member]
Debt Instrument [Line Items]
Principle amount of issued debt					$ 25,000,000
Debt instrument, description							The Yorkville SPA provided that the Convertible Debentures would be issued and sold at a purchase price equal to 96% of the applicable principal amount in three tranches as follows: (i) $10.0 million upon the signing of the Yorkville SPA, which was funded on March 21, 2023, (ii) $7.5 million upon the filing of a registration statement on Form S-1 with the SEC to register the resale by Yorkville of any shares of Common Stock issuable upon conversion of the Convertible Debentures under the Securities Act of 1933, as amended (the “Securities Act”), which was funded on April 11, 2023 and (iii) $7.5 million at the time such registration statement is declared effective by the SEC, which was funded on April 20, 2023.
Debt instrument, interest rate					7.00%
Debt maturity date					Dec. 21, 2023		Mar. 15, 2024
Debt conversion price					$ 8
Debt Instrument Principal Amount, Percentage					5.00%
Debt payment terms							The Company had the option to repay either (i) in cash, with premium equal to 5% in respect of the principal amount of such payment, or (ii) by submitting a notice for an advance under the A&R Yorkville Purchase Agreement, or a series of advances thereunder, or any combination of (i) or (ii) as determined by the Company. In the case of (ii), the proceeds from the shares sold to Yorkville are applied against the outstanding amounts.
Convertible Debentures Issued Percent					96.00%
Redemption Premium							10.00%
Securities Purchase Agreement [Member] | First installment [Member]
Debt Instrument [Line Items]
Repayment of debt prinnciple installment	$ 5,000,000
Securities Purchase Agreement [Member] | Second Installment [Member]
Debt Instrument [Line Items]
Repayment of debt prinnciple installment	15,000,000
Securities Purchase Agreement [Member] | Third Installment [Member]
Debt Instrument [Line Items]
Repayment of debt prinnciple installment	20,000,000
Securities Purchase Agreement [Member] | Oramed Note
Debt Instrument [Line Items]
Principle amount of issued debt	101,900,000
Debt instrument, description							Interest under the Oramed Note accrues at a fluctuating per annum interest rate equal to the sum of (1) greater of (x) 4% and (y) Term SOFR (as defined in the Oramed Note) and (2) 8.5%, payable in-kind on a monthly basis. Pursuant to the Oramed Note, since the outstanding principal of the Oramed Note was not repaid in full on or prior to March 21, 2024, an exit fee of approximately $3.1 million has been earned with respect to the Oramed Note, which shall be due and payable on the date on which the outstanding principal amount of the Oramed Note is paid in full. Upon the occurrence and during the continuance of an event of default under the Oramed Note, holders of more than 50% of the aggregate unpaid principal amount of the Oramed Notes may elect to accrue interest at a default rate equal to the lesser of (i) Term SOFR plus 15% or (ii) the maximum rate permitted under applicable law. Voluntary prepayments made before the one-year anniversary of the closing date of the Scilex-Oramed SPA must include a make-whole amount equal to 50% of the additional interest that would accrue on the principal amount so prepaid from the date of such prepayment through and including the maturity date. If the Oramed Note is accelerated upon an event of default, repayment is required at a mandatory default rate of 125% of the principal amount (together with 100% of accrued and unpaid interest thereon and all other amounts due in respect of the Oramed Note). The Oramed Note contains mandatory prepayment provisions requiring use of 70% of net cash proceeds from any Cash Sweep Financing (as defined in the Oramed Note) or advances under the ELOCs (as defined in the Oramed Note) to prepay the outstanding principal after the earlier of April 1, 2024 or full repayment of Acceptable Indebtedness (as defined in the Oramed Note).
Estimated fair value							$ 92,900,000
Debt Repayment Exit Fee	$ 3,100,000
Debt instrument, interest rate	4.00%
Debt maturity date	Mar. 21, 2025
Debt instrument, owned, percentage	50.00%
Debt instrument, default interest rate	15.00%
Debt instrument, percentage of interest accrued on principal amount	50.00%
Debt repayment, percentage of mandatory default rate of principal amount	125.00%
Debt repayment, percentage of mandatory default rate of accrued and unpaid interest	100.00%
Percentage of usage of cash proceeds from cash sweep financing	70.00%
Securities Purchase Agreement [Member] | Oramed Note | Monthly Basis [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate	8.50%
Securities Purchase Agreement [Member] | Oramed Note | First installment [Member]
Debt Instrument [Line Items]
Debt maturity date	Mar. 21, 2025
Securities Purchase Agreement [Member] | Oramed Note | Second Installment [Member]
Debt Instrument [Line Items]
Debt maturity date	Dec. 21, 2023
Securities Purchase Agreement [Member] | Oramed Note | Third Installment [Member]
Debt Instrument [Line Items]
Debt maturity date	Mar. 21, 2024
Securities Purchase Agreement [Member] | Oramed Note | Fourth Installment [Member]
Debt Instrument [Line Items]
Debt maturity date	Jun. 21, 2024
Securities Purchase Agreement [Member] | Oramed Note | Five Installment [Member]
Debt Instrument [Line Items]
Debt maturity date	Sep. 21, 2024
Securities Purchase Agreement [Member] | Oramed Note | Six Installment [Member]
Debt Instrument [Line Items]
Debt maturity date	Dec. 21, 2024
Tranche One | Securities Purchase Agreement [Member]
Debt Instrument [Line Items]
Principle amount of issued debt					$ 10,000,000
Tranche Two | Securities Purchase Agreement [Member]
Debt Instrument [Line Items]
Principle amount of issued debt					7,500,000
Tranche Three | Securities Purchase Agreement [Member]
Debt Instrument [Line Items]
Principle amount of issued debt					$ 7,500,000
A&R Yorkville Purchase Agreement
Debt Instrument [Line Items]
Principle amount of issued debt				15,000,000
Net cash proceeds				$ 14,400,000
Convertible Debentures Repaid							$ 4,400,000
Common Stock at a conversion price							$ 8
Outstanding debt instrument							$ 7,700,000
Change in fair value							35,000
Outstanding principal amount							$ 5,000,000
Common stock, shares issued							632,431
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Principle amount of issued debt							$ 75,000,000
Termination fees							0.50%
Facility cap maximum			95.00%
Facility cap minimum			85.00%
Outstanding debt instrument			$ 250,000
Cash on hand							$ 1,000,000
Outstanding principal amount							$ 16,300,000
Accounts receivable revolving loan facility in an aggregate amount	$ 30,000,000		$ 30,000,000
Line Of Credit Facility Interest Rate		1.50%